The largest community of pharma leaders

As pharmaceutical execs sell shares worth millions, questions arise

NEW YORK — Pfizer, Moderna, Novavax: executives at several American laboratories developing COVID-19 vaccines have recently pocketed millions of dollars by selling shares in their companies — raising questions about the propriety of such a move in the midst of a global health crisis.

On the very day that pharmaceutical giant Pfizer announced preliminary data showing its vaccine was 90 per cent effective against the coronavirus, its chief executive Albert Bourla sold shares worth US$5.6 million.



Recent Articles